Femara, Seroquel, Razadyne ER Paragraph IV Certifications Filed
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for Novartis' breast cancer agent Femara (letrozole) was filed March 2, according to FDA's May 2 updated list of filings
You may also be interested in...
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.